OBJECTIVES: We sought to evaluate the impact of baseline anxiety levels on drug placebo separation and drug and placebo response in acutely psychotic schizophrenic subjects. METHODS: In this post-hoc analysis, modified intent-to-treat Positive and Negative Syndrome Scale data were obtained from a phase 2, multi-center, 5 week, randomized, double-blind, placebo-controlled trial of KarXT in hospitalized adults with DSM-5 schizophrenia experiencing an acute exacerbation or relapse of symptoms. We investigated the impact of anxiety on drug placebo separation and drug and placebo response in 2 ways. In the first set of analyses, we dichotomized the data based on the absence or presence of anxiety symptoms. In the second set of analyses, we categorized subjects by levels of anxiety. All analyses were conducted using generalized linear models with normal distribution and identity link function. RESULTS: On average, subjects entering the trial were suffering from a moderate level of anxiety. Subjects with no baseline anxiety had a significant increase in placebo response, a decrease in drug response and did not separate drugs from placebo. With increasing levels of baseline anxiety, a larger drug placebo difference was observed. DISCUSSION: Our analyses identified that absence of anxiety at baseline was associated with a loss of signal at end of treatment between drug and placebo driven by a differential effect on placebo and treatment response. The effect observed was not related to the overall baseline symptom severity and was not mediated by improvement in anxiety itself. Interpretation of the results is caveated by the retrospective nature of the analyses.

Karuna Therapeutics Boston MA USA

Signant Health Blue Bell PA USA

Signant Health Mclean VA USA

Signant Health Prague Czech Republic

Zobrazit více v PubMed

Achim AM, Maziade M, Raymond E, Olivier D, Mérette C, Roy M-A.. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011;37(4):811–821. doi:10.1093/schbul/sbp148. PubMed DOI PMC

Naidu K, van Staden WCW, van der Linde M.. Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry. 2014;14:166. doi:10.1186/1471-244X-14-166. PubMed DOI PMC

Temmingh H, Stein DJ.. Anxiety in patients with schizophrenia: epidemiology and management. CNS Drugs. 2015;29(10):819–832. doi:10.1007/s40263-015-0282-7. PubMed DOI

Lysaker PH, Salyers MP.. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand. 2007;116(4):290–298. doi:10.1111/j.1600-0447.2007.01067.x. PubMed DOI

Pallanti S, Quercioli L, Hollander E.. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry. 2004;161(1):53–58. doi:10.1176/appi.ajp.161.1.53. PubMed DOI

Fenton WS, McGlashan TH.. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986;143(4):437–441. doi:10.1176/AJP.143.4.437. PubMed DOI

Buckley PF, Miller BJ, Lehrer DS, Castle DJ.. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383–402. doi:10.1093/schbul/sbn135. PubMed DOI PMC

Leucht S, Leucht C, Huhn M, et al. . Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–942. doi:10.1176/appi.ajp.2017.16121358. PubMed DOI

Leucht S, Chaimani A, Mavridis D, et al. . Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology. 2019;44(11):1955–1966. doi:10.1038/s41386-019-0440-6. PubMed DOI PMC

Brannan SK, Sawchak S, Miller AC, Lieberman JA, Paul SM, Breier A.. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726. doi:10.1056/NEJMoa2017015. PubMed DOI PMC

Kott A, Brannan S, Wang X, Daniel D.. The impact of aberrant data variability on drug–placebo separation and drug/placebo response in an acute schizophrenia clinical trial. Schizophrenia Bulletin Open. 2021;2(1):295. doi:10.1093/schizbullopen/sgab037. PubMed DOI PMC

Kay SR, Fiszbein A, Opler LA.. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed

Kahan BC, Rushton H, Morris TP, Daniel RM.. A comparison of methods to adjust for continuous covariates in the analysis of randomised trials. BMC Med Res Methodol. 2016;16:42. doi:10.1186/s12874-016-0141-3. PubMed DOI PMC

Matza LS, Morlock R, Sexton C, Malley K, Feltner D.. Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder. Int J Methods Psychiatr Res. 2010;19(4):223–232. doi:10.1002/mpr.323. PubMed DOI PMC

Furukawa TA, Levine SZ, Tanaka S, et al. . Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry. 2015;72(1):14–21. doi:10.1001/jamapsychiatry.2014.2127. PubMed DOI

Khan A, Lewis C, Lindenmayer J-P.. Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS). BMC Psychiatry. 2011;11:178. doi:10.1186/1471-244X-11-178. PubMed DOI PMC

Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. doi:10.1111/j.2044-8341.1959.tb00467.x. PubMed DOI

Naidu K, van Staden W, Fletcher L.. Discerning undifferentiated anxiety from syndromal anxiety in acute-phase schizophrenia. Ann Gen Psychiatry. 2020;19:26. doi:10.1186/s12991-020-00277-4. PubMed DOI PMC

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research. Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biologics Guidance for Industry; 2021. FDA-2019-D-0934. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products. Accessed January 3, 2023.